Johnson & Johnson/Omrix Win General Surgery Hemostasis Approval For Evicel
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.
Approval puts Evicel marginally ahead of ZymoGenetics’ recombinant human fibrin sealant rhThrombin, which has a Jan. 17 action date.